Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation

: The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated. Twenty-three patients who were treated with repeated CAF chemotherapy after breast cancer operation received drip-infused granisetron (3 mg/body) to prevent nausea and vomiting. Antiemetic efficacy was evaluated by means of the severity of nausea and the frequency of vomiting. The antiemetic efficacy rate of the drug was 74.4%. However, the average rate of antiemetic efficacy was 86.9% on the first through the sixth administration of the chemotherapy (first period). 75.9% on the seventh through the twelfth (second period), 48.4% on the thirteenth through the eighteenth (third period), and 31.8% on the nineteenth through the twenty-fourth (fourth period). There were significant differences in the antiemetic efficacy rate among the first, second and third periods. The antiemetic efficacy of granisetron decreased significantly by repeated CAF chemotherapy.